# Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

> **NCT02930317** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Recombinant Factor VIII (50 IU/kg)
- **DRUG:** Recombinant Factor VIII (On-demand treatment)

## Key facts

- **NCT ID:** NCT02930317
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2017-10
- **Final completion:** 2017-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02930317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02930317, "Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02930317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*